OR WAIT null SECS
January 30, 2013
At the end of February, sunny southern California will be the site for a week-long conference devoted to the development and production of biopharmaceuticals.
There are growing concerns regarding the safety of third- and fourth-generation combined oral contraceptives following media reports on blood clots (venous thromboembolism) associated with the use of more recently-introduced contraceptive products containing newer progestins such as drospirenone, gestodene and desogestrel.
January 29, 2013
In the dog-eat-dog world of federal deficit reduction in the US, there seems to be one health-related spending cut with broad bi-partisan support:
January 28, 2013
Biosimilars. They bring cheap prices to patients and healthcare payers, but for biopharmaceutical companies, such products impact the sales of innovative biopharmaceuticals.
January 25, 2013
A new international agreement to reduce mercury contamination of air and water was recently adopted by 140 countries, without a proposal that threatened to limit access to vaccines in much of the world.
January 24, 2013
Biopharmaceutical companies are touting their huge investment in R&D, which has filled the drug pipeline with more potential first-in-class medicines, including orphan drugs, personalized medicines and new therapies based on novel scientific strategies.
Six of the world’s leading health research centres have joined forces to form a global alliance that seeks to strengthen international academic and not-for-profit drug development.
January 17, 2013
Recently, after reading about the severity of this year’s flu season, I finally went and got my vaccine, which my doctor had been out of when I tried in October.
January 15, 2013
PharmTech’s February issue will feature a guest editorial by Aaron Davidson, a partner in the life sciences practice at Baker Botts, on social media and the pharmaceutical industry.